• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Praxis Precision Medicines (PRAX)

Common Shares
Sell: $314.00|Buy: $365.00|Change: 0.07 (0.02%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Address

One Broadway, 16th Floor
Cambridge
MA
USA
02142

Telephone

+1 617 300-8460

Website

https://www.praxismedicines.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Praxis Precision Medicines Inc Fourth Quarter Earnings Conference Call for 20262027-02-19T08:00:00
Praxis Precision Medicines Inc Fourth Quarter Earnings Results for 20262027-02-19T00:00:00
Praxis Precision Medicines Inc Annual Report for 20262027-02-19T00:00:00
Praxis Precision Medicines Inc Third Quarter Earnings Results for 20262026-11-05T08:00:00
Praxis Precision Medicines Inc Second Quarter Earnings Conference Call for 20262026-08-04T08:30:00
Praxis Precision Medicines Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
Praxis Precision Medicines Inc Annual General Meeting for 20262026-06-26T09:00:00
Praxis Precision Medicines Inc First Quarter Earnings Results for 20262026-05-01T00:00:00

Previous key dates

NameKey Date
TD Cowen 46th Annual Health Care Conference2026-03-02T11:50:00
TD Cowen 46th Annual Health Care Conference2026-03-02T11:50:00
Praxis Precision Medicines Inc Fourth Quarter Earnings Conference Call for 20252026-02-19T08:00:00
Praxis Precision Medicines Inc Fourth Quarter Earnings Results for 20252026-02-19T00:00:00
Praxis Precision Medicines Inc Annual Report for 20252026-02-19T00:00:00
Guggenheim Emerging Outlook: Biotech Summit 20262026-02-11T13:00:00
HCW with Praxis Medicines, Inc. (PRAX) - Deep Dive into Praxis’ Ulixacaltamide Data2025-11-24T13:00:00
Jefferies Global Healthcare Conference2025-11-18T13:30:00
Guggenheim Securities Inaugural Healthcare Innovation Conference2025-11-10T09:30:00
Praxis Precision Medicines Inc Third Quarter Earnings Results for 20252025-11-05T08:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T08:30:00
Virtual Fireside Chat with Praxis Precision Medicines Inc (PRAX)2025-08-07T11:00:00
Praxis Precision Medicines Inc Second Quarter Earnings Conference Call for 20252025-08-04T08:30:00
Praxis Precision Medicines Inc Second Quarter Earnings Result for 20252025-08-04T00:00:00
Praxis Precision Medicines Inc Annual General Meeting for 20252025-06-26T09:00:00
Praxis Precision Medicines Inc First Quarter Earnings Results for 20252025-05-02T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T11:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.